Lyon, January 25, 2022
Edelris announced today that they have entered into a new agreement for the discovery of innovative and selective ligands on biological targets of interest for Bayer, focusing on addressing new modes of action for disease control in pilot projects.
« Bayer has been a long-standing client of Edelris and we are happy to have the possibility to make the difference with Bayer again! » stated Jean-Yves Ortholand, CEO at Edelris « We will have the opportunity to demonstrate that our technologies can help a leading and global crop protection organization finding meaningful active compounds of next generation. Our team is eager to continue our relationship with this collaboration! »
Edelris will activate EDEN (Edelris Discovery ENgine), combining its dedicated AS-MS (Affinity Selection-Mass Spectrometry) screening technologies and expertise based upon with its proprietary compound library of 2M lead-like members originating from Edelris’ Keymical Space™.
The financial terms are not disclosed.
More news
About Edelris
Expanding the boundaries for your small molecule drug discovery!
Edelris is a leading Drug Discovery CRO, providing Compound Libraries, Organic & Medicinal Chemistry, High Throughput Screening, and Analytical expert services to the Pharmaceutical, Cosmetic, Crop Protection, and Biotech sectors.
Cross-fertilizing our combined experiences, knowledge, and techniques, together we break through to successful solutions for you.